Skip to main content

Table 2 Randomized controlled trials included in the review (n = 4)

From: Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD)

Study ID

Funding

Country & Setting

Intervention

Comparison

Weeks (sessions)

Total randomised

Mean age of sample

% female in sample

Diagnostics & baseline screening

Primary measures

Secondary measures

Drop-outs

Lost to follow-up

Medication

Aliyev and Aliyev 2011

None

Azerbaijan outpatients (single centre)

Lamotrigine (dose: 25–300 mg/day)

Placebo

12

80

37.7

0

CDS

CDS

Improvement

15

-

Sierra et al. 2003

None

UK outpatients (single centre)

Lamotrigine (dose: 25–250 mg/day)

Placebo

12

14

35.2

 

DSM-IV

PSE

DES

5

-

PSE

CDS

BDI

CDS

  

Simeon et al. 2004

NIMH grant

USA outpatients (single centre)

Fluoxetine (dose: 10–60 mg/day) (provided by Eli Lilly)

Placebo

10

54

36

39

SCID-D

CGI-I

HRSA

13

-

Semi-structured clinical interview

DES-DP

HRSD

DSS

LSAS

YBOCS

Panic attacks

Psychotherapy

Schoenberg et al. 2012

Medical Research Council

UK outpatient (single centre)

Electro-dermal biofeedback (8 sessions)

Sham electro-dermal biofeedback

4 (8)

32

35

25

SCID-D

CDS

-

2

-

DES

 

BAI

 

Pilkington Pilozzo Charitable Trust

        

BDI

  Â